scholarly journals Hemoptysis and Acute Respiratory Syndrome (ARDS) as Delayed-Type Hypersensitivity After FOLFOX4 Plus Bevacizumab Treatment

2013 ◽  
Vol 98 (4) ◽  
pp. 445-449 ◽  
Author(s):  
Takaaki Kobayashi ◽  
Tadahiko Masaki ◽  
Koji Kogawa ◽  
Hiroyoshi Matsuoka ◽  
Masanori Sugiyama
Keyword(s):  
Colorectal Cancer ◽  
Case Reports ◽  
Pulse Therapy ◽  
Delayed Type Hypersensitivity ◽  
Type I ◽  
Steroid Pulse ◽  
Type Iv ◽  
Bevacizumab Treatment ◽  
Tnf Α ◽  
Colorectal Cancer Patients

Abstract As there have been many multidrug regimens introduced in colorectal cancer treatment, hypersensitivity is more often encountered than in the past. Though most allergic adverse events of oxaliplatin are mainly classified as type I reaction, a limited number of case reports of type IV reaction (delayed-type hypersensitivity) have been reported. A 73-year-old man was hospitalized for receiving the third cycle of FOLFOX4 plus bevacizumab. Forty-two hours after administration, he had dyspnea and hemoptysis. Acute respiratory distress syndrome was suspected, and the patient underwent mechanical ventilation and steroid pulse therapy. Delayed-type hypersensitivity is induced by induction of inflammation via IL-1, TNF-α and IL-6. The serum level of IL-6 in patients with advanced colorectal cancers is usually greater than the normal range. Therefore, delayed-type hypersensitivity may be easily induced in those patients. We should pay special attention to delayed-type hypersensitivity in advanced colorectal cancer patients undergoing FOLFOX treatment.

Correlation of markers of oxidative damage and circulating IL6 levels with survival following treatment with bevacizumab in metastatic colorectal cancer patients.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e21024-e21024
Author(s):  
Sinead Noonan ◽  
Petra Martin ◽  
Aoife Maguire ◽  
Monika Biniecka ◽  
Miriam Tosetto ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Oxidative Damage ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Tumour Progression ◽  
Dna Adduct ◽  
Response To Treatment ◽  
Bevacizumab Treatment ◽  
Colorectal Cancer Patients ◽  
Circulating Levels

e21024 Background: Angiogenesis drives cancer growth, tumour progression and metastases. Hypoxic tumours initiate recruitment of their own blood supply and enhance expression of vascular endothelial growth factor (VEGF). Bevacizumab is a recombinant humanised monoclonal anti-VEGF antibody which prevents VEGF binding to its receptors and improves overall survival in metastatic colorectal cancer patients when combined with cytotoxic chemotherapy. Currently, Bevacizumab is indicated as a first line treatment in all metastatic colorectal cancer patients, however only 38-44% of these patients will have a response to treatment. There is no good marker to predict treatment response. The role of inflammation and oxidative damage in driving angiogenesis and clinical response to bevacizumab is poorly understood. The aim of this study was to investigate the levels of oxidative damage and inflammation in the tissue and in the circulation of patients receiving Bevacizumab. Methods: Tissue from 80 patients was constructed into tissue microarrays (TMAs) and screened by immunohistochemistry for the levels of a DNA adduct marker 8oxodG and a lipid peroxidation marker 4HNE in addition to Ki67 status. Serum was screened for 8oxodG, 4HNE and the inflammatory cytokines; IL1β, IL6, IL8, TNFα and pro-angiogenic factors; Ang 2, TGFβ, VEGF using ELISA. Data was correlated with patient survival following Bevacizumab treatment. Results: 8oxodG stromal nuclear positivity significantly correlated with survival following bevacizumab (p=0.035) and this was independent of cell proliferation status. Following multivariate analysis, circulating IL6 levels also significantly correlated with survival following bevacizumab treatment (p=0.01). Using linear regression, circulating levels of 8oxodG correlated with IL6 levels (p=0.016). Circulating Ang 2 levels correlated with IL6 (p=0.006). Conclusions: We have shown for the first time that levels of a DNA adduct marker 8oxodG and circulating levels of IL6 correlate with survival in metastatic patients receiving Bevacizumab.

scholarly journals A new ultrasound and clinical classification for management of prostatic abscess

2015 ◽  
Vol 87 (3) ◽  
pp. 246 ◽  
Author(s):  
Lucio Dell’Atti
Keyword(s):  
Ultrasound Imaging ◽  
Case Reports ◽  
Published Data ◽  
Type I ◽  
New Classification ◽  
Prostatic Abscess ◽  
Type Iv ◽  
Type V ◽  
Sonographic Pattern

Objectives: In literature, most of the published data regarding prostatic abscess (PA) are case reports, whereas there is no standardization of the diagnostic and therapeutic routines. The purpose of this study is a new classification of ultrasound imaging of PA with clinical features correlation. Material and Methods: We retrospectively analysed the ultrasound database archives and performed a MEDLINE<sup>®</sup> research of the peer reviewed literature on diagnosis and case reports of PA using the terms “prostate and abscess”. Results: PA can be classified into five Types: Type I - PA is present focally in a prostate lobe (≤ 10 mm). Type II - PA is present in a prostate lobe (&gt; 10 mm) and/or partially overcrosses the border of the midline prostatic glandular. Type III - PA is present in both glandular lobes form of multifocal areas (≤ 10 mm). Type IV - PA is present in both glandular lobes form of multifocal areas (&gt; 10 mm). Type V - PA involving intra or extraprostatic structures (bladder, urethra, seminal vesicles and prostatic capsule). The different ultrasound imaging and diagnostic criteria are listed for each type and subtype. Conclusions: The sonographic pattern of PA is usually characteristic and easily differentiated from other glandular lesions. The purpose of the study was to associate the use of TRUS to a clinical standardized classification in order to facilitate PA diagnosis and localization directing the clinician treatment to the correct management and adequate therapeutic treatment.

scholarly journals Gastric tumorigenesis after radical resection combined with adjuvant chemotherapy for colorectal cancer: two case reports and a literature review

2021 ◽  
Vol 49 (4) ◽  
pp. 030006052110070
Author(s):  
Tao Li ◽  
Guoliang Liu ◽  
Jiannan Li ◽  
Jian Cui ◽  
Xinyu Wang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Adjuvant Chemotherapy ◽  
Case Reports ◽  
Intraepithelial Neoplasia ◽  
Radical Resection ◽  
Stromal Tumor ◽  
Cancer Early Detection ◽  
Long Term Follow Up ◽  
Gastric Stromal Tumor ◽  
Colorectal Cancer Patients

Radical resection with or without adjuvant chemotherapy is a common option for stage II and III colorectal cancer. Few reports exist regarding gastric tumorigenesis, including gastric cancer, gastric intraepithelial neoplasia, and gastric stromal tumor, in patients who received this protocol as the standard treatment for colorectal cancer. We present two cases of gastric tumorigenesis in patients with colorectal cancer following radical resection combined with adjuvant chemotherapy. Both patients underwent gastrectomy and D2 lymphadenectomy for their gastric tumors; neither patient developed recurrence up to 2 years after treatment. These cases indicate that patients should be monitored closely for gastric tumorigenesis after treatment for colorectal cancer. Early detection and active surgical treatment can provide satisfactory results for colorectal cancer followed by gastric tumorigenesis. Long-term follow-up and regular examinations, especially gastroscopy, are necessary to detect gastric tumorigenesis after colorectal cancer. The focus on monitoring colorectal cancer alone in colorectal cancer patients should be changed to include a broader range of cancers in addition to precancers and other tumors, such as gastric stromal tumor.

scholarly journals Cutaneous Metastasis from Colorectal Cancer: Making Light on an Unusual and Misdiagnosed Event

Life ◽  
2021 ◽  
Vol 11 (9) ◽  
pp. 954
Author(s):  
Paola Parente ◽  
Davide Ciardiello ◽  
Luca Reggiani Bonetti ◽  
Vincenzo Famiglietti ◽  
Gerardo Cazzato ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Case Reports ◽  
Rare Event ◽  
Case Series ◽  
Cutaneous Metastasis ◽  
Cutaneous Lesions ◽  
Primary Malignancy ◽  
Visceral Metastases ◽  
History Of ◽  
Colorectal Cancer Patients

Cutaneous metastasis from solid tumors is a rare event and usually represents a late occurrence in the natural history of an advanced visceral malignancy. Rarely, cutaneous metastasis has been described in colorectal cancer patients. The most frequent cutaneous site of colorectal metastasis is the surgical scar in the abdomen following the removal of the primary malignancy, followed by the extremities, perineum, head, neck, and penis. Metastases to the thigh and back of the trunk are anecdotical. Dermatological diagnosis of cutaneous metastasis can be quite complex, especially in unusual sites, such as in the facial skin or thorax and in cases of single cutaneous lesions since metastasis from colorectal cancer is not usually the first clinical hypothesis, leading to misdiagnosis. To date, due to the rarity of cutaneous metastasis from colorectal cancer, little evidence, most of which is based on case reports and very small case series, is currently available. Therefore, a better understanding of the clinic-pathological characteristics of this unusual metastatic site represents an unmet clinical need. We present a large series of 29 cutaneous metastases from colorectal cancer with particular concerns regarding anatomic localization and the time of onset with respect to primitive colorectal cancer and visceral metastases.

scholarly journals Effects of enriched environment and probiotics on the intestinal mucosal barrier and the brain-gut axis in rats with colorectal cancer

2020 ◽  
Author(s):  
Dun Liu ◽  
Wu Xian-Yi ◽  
Huang Si-Ting
Keyword(s):  
Colorectal Cancer ◽  
Intestinal Mucosa ◽  
Muscle Thickness ◽  
Enriched Environment ◽  
Mucosal Barrier ◽  
Gut Peptides ◽  
Intestinal Mucosal Barrier ◽  
Tnf Α ◽  
Colorectal Cancer Patients

Abstract Background Enriched environment is a paradigm where animals are introduced to novel, complex, and stimulating surroundings that can protect the intestinal mucosal barrier and regulate the expression of brain-gut peptides. Probiotics can effectively protect the intestinal mucosal barrier and regulate brain-gut axis activity in colorectal cancer patients. This study assessed the effects of probiotics, enriched environment, and joint intervention on the intestinal mucosal barrier and brain-gut axis in rats with colorectal cancer. Methods We used a rat model of 1,2-dimethylhydrazine-induced colorectal cancer. Rats were housed in four different conditions for 2 weeks: enriched environment, probiotic,joint condition and normal condition. Each rat was weighed, and the intestinal mucosa and plasma levels of tumor TNF-α, IL-6, IL-10, ghrelin, CRF, occludin, BT, SIgA and the morphology of the intestinal mucosa were measured. Results enriched environment was beneficial regarding bacteria translation, plasma and intestinal mucosa levels of cytokines, plasma CRF levels, villi length and width of intestinal mucosa and hypothalamus ghrelin compared to probiotic (P < 0.05). There were no statistical differences between the enriched environment and the other groups regarding occludin, SIgA, muscle thickness or intestinal mucosa ghrelin (P > 0.05). Conclusions The effect of enriched environment was better than probiotic, especially in the intestinal mucosal immune and biological barrier in rats with colorectal cancer. However, the combination of the two was not as effective as enriched environment. In future studies, we can investigate the role of environment and probiotics in SIgA, intestinal mucosal mechanical barrier and body weight by extending the intervention time and enlarging the sample size.

scholarly journals Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients

2015 ◽  
pp. 3329 ◽  
Author(s):  
Yasuyoshi Sato ◽  
Satoshi Matsusaka ◽  
Mitsukuni Suenaga ◽  
Eiji Shinozaki ◽  
Nobuyuki Mizunuma
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Bevacizumab Treatment ◽  
Colorectal Cancer Patients

scholarly journals Association between TNF-α-308G>A and -238G>A gene polymorphisms and TNF-α serum levels in Mexican colorectal cancer patients

2016 ◽  
Vol 15 (2) ◽  
Author(s):  
I.A. Gutiérrez-Hurtado ◽  
A.M. Puebla-Pérez ◽  
J.I. Delgado-Saucedo ◽  
L.E. Figuera ◽  
G.M. Zúñiga-González ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Gene Polymorphisms ◽  
Serum Levels ◽  
Tnf Α ◽  
Colorectal Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document